kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 Spike S2 protein, His Tag (BA.1/Omicron), 100 µg  

Recombinant SARS-CoV-2 Spike S2 protein, His Tag (BA.1/Omicron), 100 µg

Recombinant SARS-CoV-2 Spike S2 protein, AA Ser 683 - Pro 1210, expressed from human 293 cells, His Tag (BA.1/Omicron)

Synonyms: Recombinant, Spike, S2 protein, Spike glycoprotein Subunit2, S glycoprotein Subunit2, Spike protein S2

More details


Availability: within 10-14 days

480,00 €

It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant SARS-CoV-2 S2 protein, His Tag (BA.1/Omicron) (S2N-C52Hf) is expressed from human 293 cells (HEK293). It contains AA Ser 686 - Pro 1213 (Accession # QHD43416.1(N764K, D796Y, N856K, Q954H, N969K, L981F, F817P, A892P, A899P, A942P, K986P, V987P)). The mutations are identified on the SARS-CoV-2 Omicron variant (Pango lineage: BA.1; GISAID clade: GRA; Nextstrain clade: 21K). Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) are introduced to prevent the formation of aggregates in the course of protein production.

Predicted N-terminus: Ser 686

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 59.9 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines"
Sepand, Bigdelou, Ho et al
Antibodies (Basel) (2022) 11 (2)
(2) "Self-derived peptides from the SARS-CoV-2 spike glycoprotein disrupting shaping and stability of the homotrimer unit"
Padariya, Daniels, Tait-Burkard et al
Biomed Pharmacother (2022) 151, 113190
(3) "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates"
Shin, Shin, Lee et al
Vaccines (Basel) (2022) 10 (5)
Showing 1-3 of 822 papers.